RxDoctor Payments Data

Louisa Tolentino, MD

Family Medicine · Montgomery, ALNPI 1770583296

Payments from drug & device makers

$10,619in general payments, 2019–2025

Across 675 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$929
  • Lilly USA, LLC$831
  • Pfizer$769
  • AbbVie$717
  • AstraZeneca$629
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$10,45898%
  • Education$1612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,619 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$104,504
Medicare patients
247
Services billed
1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate125$124,028
EliquisApixaban109$87,822
JardianceEmpagliflozin87$80,234
RybelsusSemaglutide53$60,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$53,003
FarxigaDapagliflozin Propanediol73$50,074
OzempicSemaglutide43$47,925
MounjaroTirzepatide37$38,644
TradjentaLinagliptin30$26,578
LinzessLinaclotide30$25,333
VascepaIcosapent Ethyl48$23,306
InvokanaCanagliflozin14$17,473
TrulicityDulaglutide13$14,850
Tresiba Flextouch U-100Insulin Degludec25$13,236
MovantikNaloxegol Oxalate29$12,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Dulera$262$128,510136 claims
Novo NordiskRybelsus, Ozempic$1,160$108,13796 claims
Boehringer IngelheimJardiance, Tradjenta$388$106,812117 claims
PfizerEliquis, Premarin$769$91,886124 claims
GSKTrelegy Ellipta, Breo Ellipta$929$62,07690 claims
AstraZenecaFarxiga, Symbicort$629$55,07685 claims
Lilly USA, LLCMounjaro, Trulicity$831$53,49450 claims
AbbVieLinzess, Synthroid$717$31,61196 claims
Johnson & JohnsonInvokana$555$17,47314 claims
Sumitomo Pharma America, Inc.Gemtesa$147$6,11513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →